Clinical effects of β-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials

Circulation

Volumn 98, Issue 12, 1998, Pages 1184-1191

  Lechat, Philippe ^a   Packer, Milton ^b   Chalon, Stephan ^b   Cucherat, Michel ^b   Arab, Tarek ^b   Boissel, Jean Pierre ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

Heart failure; Meta analysis; Receptors, adrenergic, ; Trials

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL; NEBIVOLOL;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK;

EID: 0032558449     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.12.1184     Document Type: Article

References (39)

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
2. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomized controlled trials. Eur Heart J. 1997;18:560-565.
3. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997;30:27-34.
4. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993; 342:1441-1446.
5. Boissel JP, Blanchard J, Panak E, Peyrieux JC, Sacks H. Considerations for the meta-analysis of randomized clinical trials: summary of a panel discussion. Control Clin Trials. 1989;10:254-281.
6. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
7. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
8. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-129.
9. Baptista J, Pike MC. Exact two sided confidence limits for the odds ratio in a 2x2 tables. Algorithm AS 115. Appl Stat. 1977;26:214-220.
10. D'Agostino RB, Weintraub M. Meta-analysis: a method for synthesizing research. Clin Pharmacol Ther. 1995;58:605-661.
11. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Orlando, Fla: Academic Press; 1985.
12. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985;72:536-546.
13. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 1990;66: 603-607.
14. Lechat P, Boutelant S, Komajda M, Gagey S, Landault C, Maistre G, Grosgogeat Y. Pilot study of cardiovascular effects of nebivolol in congestive heart failure. Drug Invest. 1991;3(suppl 1):69-81.
15. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR. β-Blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84: 2426-2441.
16. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 1993;21:1094-1100.
17. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994;23:943-950.
18. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
19. CIBIS Investigators. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study. Circulation. 1994;90: 1765-1773.
20. Eichhorn EJ, Heesch CM, Bamett JH, Alvarez LG, Pass SM, Graybum PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
21. Metra M, Nardi M, Giubbini R, Delias L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
22. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
23. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 1995;92:212-218.
24. Australia-New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet. 1997;349: 375-380.
25. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M, Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995,92:1499-1506.
26. Bristow M, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N for the MOCHA investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94: 2807-2816.
27. Packer M, Colucci WS, Sackner-Bernstein JD, Liang C, Goldsher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation. 1996;94:2793-2799.
28. Colucci WS, Packer M, Bristow MR, Gibert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas AM, for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800-2806.
29. Cohn JN, Fowler MB, Bristow MB, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, LeJemtel TH, Narahara KA, Packer M, Young ST, Holcslau TL, Lukas MA, for the US Carvedilol Heart Failure Study Group. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 1997;3: 173-179.
30. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR, Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990;88:223-229.
31. Packer M, Bristow MR, Cohn J, Colucci W, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
32. Johansson BW. Effect of beta-blockade on ventricular fibrillation- and ventricular tachycardia-induced circulatory arrest in acute myocardial infarction. Am J Cardiol. 1986;57:34F-37F.
33. 1-receptor down-regulation in heart failure. Circ Res. 1986; 59:297-309.
34. Newton GE, Parker JD. Acute effects of β,-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996;94:353-358.
35. 2-adrenergic stimulation in animals susceptible for sudden death. Circulation. 1997; 96:1914-1922.
36. Reid JL, Whyte KF, Struthers AD Epinephrine-induced hypokalemia: the role of beta-adrenoceptors. Am J Cardiol. 1986;57:23F-27F.
37. Downey SE, Lee JC, Contribution of α-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy. Circ Res. 1983;52: 471-478.
38. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85: 790-804.
39. 1-adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers. Circulation. 1991;84:1732-1740.